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ABSTRACT
Objective: The aim of this multicenter, case-control study was to investigate the prevalence and
severity of impulsive-compulsive behaviors (ICBs) in a cohort of patients with parkin-associated
Parkinson disease (PD) compared to a group of patients without the mutation.
Methods: We compared 22 patients with biallelic parkin mutations (parkin-PD) and 26 patients
negative for parkin, PINK1, DJ-1, andGBAmutations (PD-NM), matched for age at onset, disease
duration, levodopa, and dopamine agonist equivalent daily dose. A semistructured interview was
used to diagnose each of the following ICBs: compulsive sexual behavior, compulsive buying,
binge eating, punding, hobbyism, and compulsive medication use. The Questionnaire for
Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale (QUIP-RS) was adopted to
rate ICB severity.
Results: Frequency of patients with at least one ICB was comparable between parkin-PD and
PD-NM. Nevertheless, when analyzing the distribution of specific ICBs, a higher frequency of
compulsive shopping, binge eating, and punding/hobbyism was found in the parkin-PD group.
Compared to PD-NM, parkin-PD patients with ICB had younger onset age and higher fre-
quency of smokers; in 5 patients, ICB had predated PD onset. Total and partial (compulsive
buying, compulsive sexual behavior, binge eating, hobbyism/punding) QUIP-RS scores were
higher in patients with parkin-PD compared to patients with PD-NM. Logistic regression anal-
ysis showed that the presence of parkin mutations was associated with smoking status and
higher QUIP-RS total score.
Conclusions: Our data expand the parkin-associated phenotypic spectrum demonstrating higher
frequency and severity of specific ICBs, and suggesting an association between the parkin geno-
type, smoking status, and ICB severity. Neurology® 2016;87:1436–1441
GLOSSARY
D-Ag5 dopamine agonist; DSM-IV5 Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition); EOPD5 early-
onset Parkinson disease; ICB 5 impulsive-compulsive behavior; LEDD 5 levodopa equivalent daily dose; OCS 5 obsessive-
compulsive symptoms; parkin-PD 5 Parkinson disease with parkin mutation; PD 5 Parkinson disease; PD-NM 5 Parkinson
disease–negative for mutations; QUIP-RS 5 Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease–
Rating Scale.
The term early-onset Parkinson disease (EOPD) refers to Parkinson disease (PD) with age at onset
between the third and the fifth decade, slow progression, good response to levodopa treatment,
and low burden of cognitive symptoms.1,2 However, patients with EOPD are more likely to
develop psychiatric and behavioral disturbances, specifically depression, anxiety, and impulsive-
compulsive behaviors (ICBs).3 These include impulse control disorders such as pathologic
gambling, compulsive sexual behavior, compulsive buying and binge eating, and compulsive
behaviors such as punding and compulsive use of dopamine replacement therapy (also known as
dopamine dysregulation syndrome).4
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EOPDmight be inherited in autosomal reces-
sive fashion, and it is most frequently caused by
biallelic mutations in the parkin gene.5 Previous
studies aiming to define the neuropsychiatric
profile of parkin-associated PD (parkin-PD) have
failed to demonstrate a higher frequency of either
depression6 or obsessive-compulsive symptoms
(OCS)7 in symptomatic carriers of parkin muta-
tions as compared to noncarriers. Nevertheless,
no study has systematically explored the occur-
rence and spectrum of ICB in parkin-PD. There-
fore, it remains unclear whether ICB might be
related to specific genetic mutations or simply to
an early age at onset, as previously reported.4
The aim of this multicenter, case-control
study was to investigate the prevalence and
severity of ICB in a cohort of patients with
parkin-PD compared to a group of patients
with nonmutated PD (PD-NM) matched
for demographic and clinical features.
METHODS Selection of patients. From the genetic database
at the CSS Mendel Institute in Rome, including an overall
number of 2,124 patients with PD, of whom 791 had EOPD
(age at onset ,50 years), we identified 36 patients who were
carriers of pathogenic biallelic mutations of the parkin gene
(parkin-PD). Twenty-two patients with parkin-PD agreed to
take part in this study (table e-1 at Neurology.org). Referral
centers were 4 tertiary movement disorders outpatient clinics
based in Rome, Naples, Salerno, and Messina. From the same
database, we selected a cohort of 26 controls with EOPD
(PD-NM) in whom we excluded point mutations and exon
rearrangements in the parkin gene. Moreover, in all cases and
controls, we excluded the occurrence of point mutations, small
insertions/deletions, and splice-site mutations in the PINK1,
DJ-1, and GBA genes by direct Sanger sequencing; we also
excluded the presence of single or multiexon deletions or
multiplications of PINK1, DJ-1, and SNCA by multiplex
ligation-dependent probe amplification analysis. Furthermore,
we used TaqMan genotyping to exclude the Contursi mutation
p.A53T in the SNCA gene and the common mutations
p.G2019S and p.R1441C in the LRRK2 gene.
Parkin-PD and PD-NM patients were matched for the fol-
lowing demographic and clinical features: sex, age at study entry,
age at disease onset, disease duration, PD phenotype, most
affected side, and levodopa equivalent daily dose (LEDD).8
LEDD was also considered in terms of dopamine agonist
(D-Ag) LEDD. Smoking habits were also retrieved (smoker/non-
smoker at study entry). In all patients, the motor section of the
Unified Parkinson’s Disease Rating Scale, Part III, was assessed in
the “on” state to evaluate disease severity. The presence/absence
of the following psychiatric and cognitive features was recorded:
psychosis (illusions, hallucinations, delusions) according to
National Institute of Neurological Disorders and Stroke/National
Institute of Mental Health criteria,9 and depression and dementia
according to DSM-IV criteria. The presence of rapid eye move-
ment sleep behavior disorder was diagnosed based on a single
question as in Postuma et al.10: “Have you ever been told, or
suspected yourself, that you seem to ‘act out your dreams’ while
asleep (for example, punching, flailing your arms in the air, mak-
ing running movements, etc.)?”
ICB assessment. A semistructured interview using accepted
diagnostic criteria11 for pathologic gambling, compulsive buying,
compulsive sexual behavior, binge eating, punding, and compul-
sive use of dopamine replacement therapy (anytime in the past 6
months) was used to reach the diagnosis of each of these ICBs. In
addition, the Questionnaire for Impulsive-Compulsive Disorders
in Parkinson’s Disease–Rating Scale (QUIP-RS), a rating scale
designed to measure severity of ICB in PD, was administered to
all patients.12,13 The QUIP-RS is a patient-filled questionnaire
composed by 4 questions for each ICB, which have to be
answered on a 5-point Likert scale. Total impulse control
disorder score ranges from 0 to 64; total QUIP-RS score ranges
from 0 to 112. In all patients diagnosed with ICB, we also
evaluated duration of ICB, their occurrence before disease
onset, and presence of a positive family history of ICB or
alcohol and drug abuse.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the ethic committee of the
recruiting centers and conformed to the Declaration of Helsinki.
All patients gave their written informed consent before
participation.
Statistical analysis. Comparisons between groups were made
using the Fisher exact test or the x2 test for categorical variables.
Nonparametric Mann-Whitney U test was used to compare
continuous variables. Correlations between QUIP-RS and age
Table 1 Demographic and clinical features of patients with parkin-PD and
PD-NM
Parkin-PD (n 5 22) PD-NM (n 5 26) p Value
Sex, F/M 9/13 9/17 0.7
Age, y 52.6 6 10.9 55.1 6 8.5 0.2
Age at onset, y 31.2 6 10.6 36.9 6 8.1 0.06
Disease duration, y (range) 21.9 6 10.9 (3–43) 18.2 6 9.8 (5–46) 0.2
UPDRS-III score 18.9 6 9.6 21.0 6 8.5 0.5
LEDD, mg 707.9 6 523.3 868.3 6 505.0 0.1
D-Ag LEDD, mg 159.7 6 131.4 231.4 6 210.3 0.6
Phenotype of PD, T/AR 13/9 13/13 0.5
Most affected side, R/L/U 6/14/2 10/16/0 0.2
RBD, yes/no 6/15 3/23 0.2
Depression, yes/no 8/14 15/11 0.1
Psychosis, yes/no 1/21 5/21 0.2
Dementia, yes/no 3/19 1/25 0.3
Smoking, yes/no 9/13 1/25 0.003a
ICB, yes/no 15/7 13/13 0.2
QUIP-RS score 21.9 6 19.1 6.7 6 8.5 0.02a
Abbreviations: AR 5 akineto-rigid; D-Ag 5 dopamine agonists; ICB 5 impulsive-compulsive
behavior; LEDD 5 levodopa equivalent daily dose; parkin-PD 5 Parkinson disease with
parkin mutation; PD-NM 5 Parkinson disease–negative for mutations; QUIP-RS 5 Question-
naire for Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale; RBD 5 rapid
eye movement sleep behavior disorder; T 5 tremor dominant; U 5 unclear; UPDRS-III 5
Unified Parkinson’s Disease Rating Scale, Part III.
Values reported are means 6 SD. Categorical variables compared by Fisher exact test.
a Indicates differences (p , 0.05).
Neurology 87 October 4, 2016 1437
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
at onset, disease duration, LEDD, D-Ag LEDD, and ICB
duration were explored by Spearman rank correlation. Logistic
regression was used to verify the association between ICB
(presence/absence) and the following variables: age at onset,
LEDD, D-Ag LEDD, and smoking status. Moreover, logistic
regression was also used to test possible associations between
mutation carrier status (presence/absence of biallelic mutations
in the parkin gene) and the following variables: QUIP-RS, ICB
duration, smoking status, and ICB before PD onset. Significance
level was set at p, 0.05. Unless otherwise stated, data are given as
mean 6 SD.
RESULTS Parkin-PD (n 5 22) and PD-NM (n 5
26) were comparable for all the demographic and
clinical variables taken into account but smoking
habit, which was more frequent in the parkin-PD
group (p 5 0.003; table 1).
The frequency of patients with at least one ICB
was comparable between parkin-PD and PD-NM
(table 1). Nevertheless, when analyzing distribution
of specific ICBs in each group, Fisher exact test disclosed
differences between the 2 groups, with higher frequency
of compulsive shopping, binge eating, and punding/
hobbyism in the parkin-PD group (figure 1). Moreover,
QUIP-RS scores were higher in the parkin-PD com-
pared to the PD-NM group (table 1).
When comparing only patients with ICB, the 2
groups of patients remained similar for most demo-
graphical and clinical features, except for a younger
age at PD onset, a higher frequency of smokers than
in the PD-NM group, and a lower LEDD in parkin-
PD (table 2). Again, the severity of ICB, as measured
by total QUIP-RS, was greater in the parkin-PD
group compared to PD-NM (table 2), with higher
values in the subscores related to compulsive buy-
ing, compulsive sexual behavior, binge eating, and
hobbyism/punding (figure 2). Accordingly, 2-way
analysis of covariance adjusted for age at onset con-
firmed that patients with parkin-PD scored higher at
QUIP-RS (F 5 9.5, p 5 0.005).
In addition, we compared in the parkin-PD group
patients with (n 5 15) and without (n 5 7) ICB;
we were unable to disclose any difference for age (p5
0.1), age at onset (p 5 0.07), disease duration (p 5
0.7), total LEDD (p 5 0.2), or D-Ag LEDD
(p 5 0.1). Similar findings were demonstrated in
the PD-NM group categorizing patients by presence
(n 5 13) or absence (n 5 13) of ICB (age: p 5 0.6,
age at onset: p5 0.6, disease duration: p5 0.2, total
LEDD: p 5 0.6, or D-Ag LEDD: p 5 0.9).
Univariate correlational analysis in patients with
ICB disclosed a positive relation between QUIP-RS
and ICB duration (p 5 0.03, r 5 0.4) but not with
age at onset (p 5 0.09, r 5 20.3). No correlations
were found between QUIP-RS and disease duration,
total LEDD, or D-Ag LEDD. Logistic regression
analysis (table 3) did not demonstrate any association
of ICB with presence of parkin mutations, age at
onset, or D-Ag LEDD, whereas association with age
at onset and disease duration showed a statistical
trend. Nevertheless, the parkin genotype was associ-
ated with smoking status and higher QUIP-RS total
score (table 3). Finally, multiple linear regression
analysis did not show an association of QUIP-RS
with total LEDD (p 5 0.27), D-Ag LEDD (p 5
0.50), age at onset (p 5 0.15), or disease duration
(p 5 0.48).
DISCUSSION Several conditions have been estab-
lished as risk factors for ICB in PD, including youn-
ger age, male sex, exposure to D-Ag and levodopa,
smoking habit, marital status, and family history of
gambling problems.4,14 However, it is still unknown
whether genetic mutations represent predisposing
factors for ICB. Recently, ICB was reported in 3
patients carrying mutations in PINK1, another gene
responsible for autosomal recessive EOPD. They all
presented hypersexuality, compulsive shopping, and
binge eating; in addition, punding was also present in
one patient.1 A similar behavioral profile was reported
in 2 brothers with PINK1 mutation respectively pre-
senting with pathologic gambling many years before
PD onset and hypersexuality, punding, and hypoma-
nia15 and in one patient with PINK1 mutation pre-
senting with compulsive use of dopaminergic
medications.16 Besides these case reports, no study
has systematically evaluated the frequency and sever-
ity of these behavioral complications in autosomal
recessive EOPD.
Figure 1 ICBs in parkin-PD and nonmutated PD
Frequency of specific impulsive-compulsive behaviors (ICBs) in parkin homozygous and in
nonmutated Parkinson disease (PD-NM). Parkin-PD disclosed a higher frequency of compul-
sive shopping, binge eating, punding/hobbysim, and abuse of PD medications.
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In this case-control study, we sought to determine
whether parkin-related EOPD might be associated
with a higher frequency of ICB by assessing 2 cohorts
of patients, one with parkin-mutated PD and one
with nonmutated PD comparable for several variables
involved in ICB development (age, age at onset, dis-
ease duration, LEDD, D-Ag LEDD). Although the
occurrence of ICB did not correlate with the parkin
genotype, parkinmutations influenced both the onset
and severity of specific behavioral disturbances in the
impulsive-compulsive spectrum. In particular, ICB
was overall more severe in parkin carriers who also
disclosed a higher frequency and severity of compul-
sive shopping, binge eating, and punding. Regarding
hypersexuality, patients with parkin-PD reported
a similar frequency but a more severe clinical expres-
sion. Moreover, ICB tended to occur earlier in pa-
tients with the parkin mutation, sometimes predating
PD onset.
Univariate correlational analysis revealed a correla-
tion of QUIP-RS with ICB duration. In line with this
finding, it is possible to speculate that the observed
increased severity in patients with the parkin muta-
tion may be at least in part influenced by the age at
PD onset, which tended to be younger in the parkin-
PD group. However, the effect of genotype on
QUIP-RS remained when adjusting for age at onset;
in addition, age at onset was not correlated with
QUIP-RS, neither in the univariate analysis nor in
multiple linear regression analysis. These differences
are also unlikely to depend on disparities in dopami-
nergic medication dosage, since patients with and
without parkin mutation were matched both for total
LEDD and D-Ag LEDD; nevertheless, the patients
with parkin-PD and ICB had a lower total LEDD,
supporting the hypothesis that they might be more
sensitive to developing ICB with a lower dose of
dopaminergic medications.
A novel datum from our study is the association
between the parkin genotype and smoking status.
This might have also accounted for the association
between smoking and ICB, considering that smoking
habit was more frequent in patients with parkin-PD
and ICB compared to the nonmutated ICB group.
Only one study had reported an inverse association
between parkin mutation and smoking, demonstrat-
ing a higher frequency of parkin mutations among
never-smoker Sikh Indians, in whom smoking is for-
bidden by religious texts.17 The relationship between
smoking and PD has been explored in several studies
in sporadic PD, which demonstrated an inverse asso-
ciation between PD and smoking,18 likely to be
caused by low-sensation-seeking personality traits
caused by dopaminergic denervation.19 Conversely,
smoking has been positively associated with ICB in
PD,4,20 in a dose-dependent manner and also inde-
pendently by D-Ag use.21 Recent studies showed that
smoking habits can result in motor and nonmotor
correlates in PD, and, thus, nicotine and other
Figure 2 Severity of ICB in parkin-PD and nonmutated PD
Patients with parkin-PD disclose higher Questionnaire for Impulsive-Compulsive Disorders in
Parkinson’s Disease–Rating Scale (QUIP-RS) scores for the following impulsive-compulsive
behaviors (ICBs) compared to nonmutated Parkinson disease (PD-NM): compulsive shopping,
hypersexuality, punding/hobbyism, abuse of PD medication.
Table 2 Demographic and clinical features of patients with PD and ICB
according to mutation status
Parkin-PD (n 5 15) PD-NM (n 5 13) p Value
Sex, M/F 8/7 9/4 0.2
Age, y 50.5 6 9.6 54.0 6 7.4 0.2
Age at onset, y 28.9 6 9.2 37.3 6 9.9 0.02a
Disease duration, y 22.5 6 10.3 16.8 6 9.7 0.09
UPDRS-III score 19.7 6 7.4 18.2 6 6.2 0.5
LEDD, total, mg 732.0 6 514.4 969.0 6 560.2 0.01a
LEDD D-Ag, mg 208.9 6 124.7 196.7 6 152.6 0.8
RBD, yes/no 4/11 1/12 0.3
Depression, yes/no 7/8 8/5 0.5
Psychosis, yes/no 1/14 3/10 0.3
Dementia, yes/no 2/13 0/13 0.5
Smoking, yes/no 7/8 1/12 0.04a
Family history of ICB, yes/no 3/11 0/13 0.2
ICB duration, y 9.5 6 6.5 5.9 6 4.5 0.08
ICB before PD onset, yes/no 5/10 0/13 0.04a
QUIP-RS score 31.5 6 15.2 13.5 6 7.2 0.001a
Abbreviations: D-Ag 5 dopamine agonists; ICB 5 impulsive-compulsive behavior; LEDD 5
levodopa equivalent daily dose; parkin-PD 5 Parkinson disease with parkin mutation; PD 5
Parkinson disease; PD-NM 5 Parkinson disease–negative for mutations; QUIP-RS 5 Ques-
tionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale; RBD 5
rapid eye movement sleep behavior disorder; UPDRS-III 5 Unified Parkinson’s Disease Rat-
ing Scale, Part III.
Values reported are means 6 SD. Categorical variables compared by Fisher exact test.
a Indicates differences (p , 0.05).
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cigarette components have been suggested to have
a broad action on the heterogeneity of the clinical
phenotype.22 Thus, it is tempting to speculate that
smoking habit could somehow influence the severity
of ICB in patients with parkin mutation. Supporting
this hypothesis, IV administration of nicotine in the
rat is associated with increased glucose utilization and
increased dopaminergic transmission in the shell of
the nucleus accumbens,23 a limbic area involved in
reward and addiction. Alternatively, patients with
parkin-PDmight be more prone to smoking as a man-
ifestation of their ICB, as smoking and pathologic
gambling also frequently co-occur in nonparkinso-
nian patients.24
OCS were also reported to be more severe in pa-
tients with PD and ICB.7 Of note, a recent study
showed lower levels of OCS in parkin-mutated com-
pared to nonmutated PD, but highlighted a trend for
higher OCS levels in asymptomatic parkin mutation
carriers compared to noncarriers, suggesting that
OCS may represent an early nonmotor dopamine-
dependent feature.7 In this light, although we were
not able to assess OCS in our patients, our observa-
tion of ICB predating PD onset in some parkinmuta-
tion carriers could also point at ICB as a potential
early sign of dopaminergic dysfunction. Further stud-
ies are needed to thoroughly explore the association
between OCS and ICB in patients with parkin-PD.
Besides these potential correlations, the mecha-
nism underlying the increased ICB severity in
parkin-associated PD still remains to be elucidated.
An intriguing explanation may relate to the selective
neurodegeneration of frontostriatal-limbic structures
observed in parkin carriers, as patients with PD and
ICB were found to exhibit alterations of cortical
thickness in the frontostriatal-limbic circuitry.13
Indeed, a functional neuroimaging study using an
automated segmentation MRI method demonstrated
decrease of gray matter volume in the caudate nuclei
of parkin-PD compared to PD-NM24; a similar find-
ing was reported also by functional imaging studies by
PET and SPECT, which demonstrated a severe dopa-
minergic denervation both in the caudate nuclei and
the putamen in symptomatic parkin-PD.25,26 The
caudate nucleus is part of the ventral striatum and
is connected with the orbitofrontal cortex, an area
involved in reward and stimulus–reinforcement asso-
ciation learning27; specifically, the caudate nucleus
receives converging projections from orbitofrontal
cortex, dorsolateral prefrontal cortex, and parietal re-
gions, supporting the role of this structure in the
integration of reward, attention, and executive pro-
cesses that occurs during spatial reinforcement learn-
ing.28 In this light, it can be foreseen that functional
neuroimaging studies would greatly help in the
understanding of the neural basis of ICB symptoms
in patients with parkin-PD.
We acknowledge that the number of study partic-
ipants is small, because of the rarity of these genetic
conditions. Indeed, our study sample is comparable
to previous cohort studies exploring cognition and
depressive symptoms in parkin-PD.6,7,29 Further stud-
ies in distinct cohorts of patients with and without the
parkin mutation will be required to replicate our
findings.
Our data expand the spectrum of parkin-associated
PD phenotype demonstrating a higher frequency and
severity of specific ICB related to compulsive behav-
iors; furthermore, our findings suggest an association
between the parkin genotype and smoking status,
which needs to be further explored in relation to the
development of impulsive-compulsive behaviors.
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